tbuckley/cabot-search huggingface dataset:
Homo‐Dyad with Outer Hydration Layer Approach for Developing NIR‐II Chromophore of High Stability and Water‐Solubility as Injectable and Sprayable Optical Probe
Authors: Zunpan She, Rong Li, Fang Zeng, Shuizhu Wu
Journal: Advanced Healthcare Materials (2024)

Dyes with extended conjugate structures are the focus of extensive design and synthesis efforts, aiming to confer unique and improved optical and electronic properties. Such advancements render these dyes applicable across a wide spectrum of uses, ranging from second-window near-infrared (NIR-II) bioimaging to organic photovoltaics. Nevertheless, the inherent benefits of long conjugation are often accompanied by persistent challenges like aggregation, fluorescence quenching, absorption blueshift, and low stability and poor water solubility. Herein, a unique structural design strategy termed "homo-dyad with outer hydration layer" is introduced to address these inherent problems, tailored for the development of imaging probes exhibiting long absorption/emission wavelengths. This approach involves bringing two heptamethine cyanines together through a flexible linker, forming a homo-dyad structure, while strategically attaching four polyethylene glycol (PEG9) chains to the terminal heterocycles. This approach imparts excellent water solubility, biocompatibility, and enhanced chemical, photo-, and spectral stability for the dyes. Utilizing this strategy, a biomarker-activatable probe (HD-FL-4PEG9-N) for NIR-II fluorescent and 3D multispectral optoacoustic tomography imaging is developed, and its effectiveness in disease visualization. It can not only serve as an injectable probe for acute kidney injury imaging due to its high water solubility, but also a sprayable probe for imaging bacterial-infected wounds.
Capacity for the management of kidney failure in the International Society of Nephrology Eastern and Central Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)
Authors: Caner Alparslan, Jolanta Malyszko, Fergus J. Caskey, Mirna Aleckovic-Halilovic, Zdenka Hrušková, Silvia Arruebo, Aminu K. Bello, Sandrine Damster, Jo-Ann Donner, Vivekanand Jha, David W. Johnson, Adeera Levin, Charu Malik, Masaomi Nangaku, Ikechi G. Okpechi, Marcello Tonelli, Feng Ye, Vladimir Tesar, Sanjin Racki, Atefeh Amouzegar, Zehra Aydin, Myftar Barbullushi, Sibel Bek, Inga Arune Bumblyte, Yeoungjee Cho, M. Razeen Davids, Sara N. Davison, Constantinos Deltas, Hassane M. Diongole, Smita Divyaveer, Udeme E. Ekrikpo, Isabelle Ethier, Agnes B. Fogo, Winston Wing-Shing Fung, Anukul Ghimire, Eva Honsova, Ghenette Houston, Htay Htay, Kwaifa Salihu Ibrahim, Georgina Irish, Kailash Jindal, Rümeyza Kazancıoğlu, Dearbhla M. Kelly, Magdalena Krajewska, Mario Laganovic, Rowena Lalji, Aisha M. Nalado, Radomir Naumovic, Brendon L. Neuen, Milena Krasimirova Nikolova-Vlahova, Ionut Nistor, Timothy O. Olanrewaju, Mohamed A. Osman, Mai Ots-Rosenberg, Anna Petrova, Ludmila Podracka, Halima Resic, Parnian Riaz, Laszlo Rosivall, Syed Saad, Aminu Muhammad Sakajiki, Emily See, Mehmet Sukru Sever, Stephen M. Sozio, Goce Spasovski, Sophanny Tiv, Serhan Tuglular, Somkanya Tungsanga, Andrea Viecelli, Marina Wainstein, Emily K. Yeung, Deenaz Zaidi
Journal: Kidney International Supplements (2024)
Long-Term Symptoms Associated With SARS-CoV-2 Infection Among Blood Donors
Authors: Melisa M. Shah, Bryan R. Spencer, Jade James-Gist, James M. Haynes, Leora R. Feldstein, Susan L. Stramer, Jefferson M. Jones, Sharon H. Saydah
Journal: JAMA Network Open (2024)

Importance Long-term symptoms, lasting more than 4 consecutive weeks after acute COVID-19 disease, are an important consequence of SARS-CoV-2 infection. Many prior studies have lacked a non–SARS-CoV-2–infected control population to distinguish background prevalence of symptoms from the direct impact of COVID-19 disease. Objective To examine the prevalence of long-term physical and mental health symptoms associated with SARS-CoV-2 infection in a large population of blood donors based on self-report and serologic test results. Design, Setting, and Participants This cross-sectional study included American Red Cross blood donors (aged ≥18 years) who were surveyed between February 22 and April 21, 2022, about new long-term symptoms arising after March 2020 and their SARS-CoV-2 infection status. All participants underwent at least 1 serologic test for antinucleocapsid antibodies between June 15, 2020, and December 31, 2021. Exposures SARS-CoV-2 infection as defined by a self-reported, confirmed acute infection or antinucleocapsid antibody positivity. Main Outcomes and Measures New long-term symptoms since March 2020, including 5 symptom categories (neurologic, gastrointestinal, respiratory and cardiac, mental health, and other). Results Among 818 361 individuals who received the survey, 272 965 (33.4%) responded, with 238 828 meeting the inclusion criteria (138 576 [58.0%] female; median [IQR] age, 59.0 [47.0-67.0] years). Of the 83 015 individuals with a history of SARS-CoV-2 infection, 43.3% reported new long-term symptoms compared with 22.1% of those without a history of SARS-CoV-2 infection. After controlling for age, sex, race and ethnicity, and number of underlying conditions, those with a history of SARS-CoV-2 infection had an increased odds of new long-term symptoms compared with those without (adjusted odds ratio [AOR], 2.55; 95% CI, 2.51-2.61). Female sex and a history of chronic conditions were associated with new long-term symptoms. Long-term symptoms in the other category (AOR, 4.14; 95% CI, 4.03-4.25), which included changes in taste or smell, and the respiratory and cardiac symptom categories (AOR, 3.21; 95% CI, 3.12-3.31) were most associated with prior SARS-CoV-2 infection. Mental health long-term symptoms were also associated with prior SARS-CoV-2 infection (AOR, 1.05; 95%, CI, 1.02-1.08). Conclusions and Relevance This study’s findings suggest that long-term symptoms lasting more than 4 weeks are common in the adult population, but there is a significantly higher prevalence among those with SARS-CoV-2 infection. Continued efforts to define and track long-term sequelae of SARS-CoV-2 using a control group without infection and serologic information to include those who had asymptomatic or unidentified infections are needed.
Impact of Circulating Tumor Cell–Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer
Authors: Hyungseok Cho, Seok-Soo Byun, Nak-Hoon Son, Jae Il Chung, Won Ik Seo, Chan Ho Lee, Todd M. Morgan, Ki-Ho Han, Jae-Seung Chung
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Prostate-specific membrane antigen (PSMA)–based images, which visually quantify PSMA expression, are used to determine prostate cancer micrometastases. This study evaluated whether a circulating tumor cell (CTC)–based transcript platform, including PSMA mRNA, could help identify potential prognostic markers in prostate cancer. Experimental Design: We prospectively enrolled 21 healthy individuals and 247 patients with prostate cancer [localized prostate cancer (LPCa), n = 94; metastatic hormone–sensitive prostate cancer (mHSPC), n = 44; and metastatic castration-resistant prostate cancer (mCRPC), n = 109]. The mRNA expression of six transcripts [PSMA, prostate-specific antigen (PSA), AR, AR-V7, EpCAM, and KRT 19] from CTCs was measured, and their relationship with biochemical recurrence (BCR) in LPCa and mCRPC progression-free survival (PFS) rate in mHSPC was assessed. PSA-PFS and radiological-PFS were also calculated to identify potential biomarkers for predicting androgen receptor signaling inhibitor (ARSI) and taxane-based chemotherapy resistance in mCRPC. Results: CTC detection rates were 75.5%, 95.3%, and 98.0% for LPCa, mHSPC, and mCRPC, respectively. In LPCa, PSMA [hazard ratio (HR), 3.35; P = 0.028) and PSA mRNA (HR, 1.42; P = 0.047] expressions were associated with BCR. Patients with mHSPC with high PSMA (HR, 4.26; P = 0.020) and PSA mRNA (HR, 3.52; P = 0.042) expressions showed significantly worse mCRPC-PFS rates than those with low expression. Increased PSA and PSMA mRNA expressions were significantly associated with shorter PSA-PFS and radiological PFS in mCPRC, indicating an association with drug resistance. Conclusions: PSMA and PSA mRNA expressions are associated with BCR in LPCa. In advanced prostate cancer, PSMA and PSA mRNA can also predict rapid progression from mHSPC to mCRPC and ARSI or taxane-based chemotherapy resistance.
Application of the Universal Definition of Myocardial Infarction in Clinical Practice in Scotland and Sweden
Authors: Caelan Taggart, Andreas Roos, Erik Kadesjö, Atul Anand, Ziwen Li, Dimitrios Doudesis, Kuan Ken Lee, Anda Bularga, Ryan Wereski, Matthew T. H. Lowry, Andrew R. Chapman, Amy V. Ferry, Anoop S. V. Shah, Anton Gard, Bertil Lindahl, Gustaf Edgren, Nicholas L. Mills, Dorien M. Kimenai
Journal: JAMA Network Open (2024)

Importance Whether the diagnostic classifications proposed by the universal definition of myocardial infarction (MI) to identify type 1 MI due to atherothrombosis and type 2 MI due to myocardial oxygen supply-demand imbalance have been applied consistently in clinical practice is unknown. Objective To evaluate the application of the universal definition of MI in consecutive patients with possible MI across 2 health care systems. Design, Setting, and Participants This cohort study used data from 2 prospective cohorts enrolling consecutive patients with possible MI in Scotland (2013-2016) and Sweden (2011-2014) to assess accuracy of clinical diagnosis of MI recorded in hospital records for patients with an adjudicated diagnosis of type 1 or type 2 MI. Data were analyzed from August 2022 to February 2023. Main Outcomes and Measures The main outcome was the proportion of patients with a clinical diagnosis of MI recorded in the hospital records who had type 1 or type 2 MI, adjudicated by an independent panel according to the universal definition. Characteristics and risk of subsequent MI or cardiovascular death at 1 year were compared. Results A total of 50 356 patients were assessed. The cohort from Scotland included 28 783 (15 562 men [54%]; mean [SD] age, 60 [17] years), and the cohort from Sweden included 21 573 (11 110 men [51%]; mean [SD] age, 56 [17] years) patients. In Scotland, a clinical diagnosis of MI was recorded in 2506 of 3187 patients with an adjudicated diagnosis of type 1 MI (79%) and 122 of 716 patients with an adjudicated diagnosis of type 2 MI (17%). Similar findings were observed in Sweden, with 970 of 1111 patients with adjudicated diagnosis of type 1 MI (87%) and 57 of 251 patients with adjudicated diagnosis of type 2 MI (23%) receiving a clinical diagnosis of MI. Patients with an adjudicated diagnosis of type 1 MI without a clinical diagnosis were more likely to be women (eg, 336 women [49%] vs 909 women [36%] in Scotland; P &amp;amp;lt; .001) and older (mean [SD] age, 71 [14] v 67 [14] years in Scotland, P &amp;amp;lt; .001) and, when adjusting for competing risk from noncardiovascular death, were at similar or increased risk of subsequent MI or cardiovascular death compared with patients with a clinical diagnosis of MI (eg, 29% vs 18% in Scotland; P &amp;amp;lt; .001). Conclusions and Relevance In this cohort study, the universal definition of MI was not consistently applied in clinical practice, with a minority of patients with type 2 MI identified, and type 1 MI underrecognized in women and older persons, suggesting uncertainty remains regarding the diagnostic criteria or value of the classification.
Time to Review Air Quality Activity Guidelines
Authors: Sumil K. Thakrar
Journal: JAMA Network Open (2024)

One strategy to reduce the health burden of air pollution is to not pollute so much; another is to limit how much pollution people breathe in.The US has pursued both emissions-related and exposurerelated interventions.Twenty-five years ago, the US Environmental Protection Agency (EPA) first promulgated activity guidelines, an exposure-related intervention that advocates remaining indoors and avoiding vigorous exercise on days when air pollution levels are unhealthy.Even relatively clean air is associated with health harms, 1 but what counts as unhealthy is codified by the EPA Air Quality Index (AQI), a mapping of criteria pollutant concentrations to categories such as good, unhealthy, and
Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)
Authors: Steven E. Nissen, Kathy Wolski, Gerald F. Watts, Michael J. Koren, Henry Fok, Stephen J. Nicholls, David A. Rider, Leslie Cho, Steven Romano, Carrie Melgaard, Curtis Rambaran
Journal: JAMA (2024)

Lipoprotein(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis, with no pharmacological treatments approved by regulatory authorities.
Artificial Intelligence and Ethical Frameworks in Pediatrics
Authors: Kai Liu
Journal: JAMA Pediatrics (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial
Authors: David E. Kandzari, Michael A. Weber, Atul Pathak, James P. Zidar, Manish Saxena, Shukri W. David, Roland E. Schmieder, Adam J. Janas, Christopher Langer, Alexandre Persu, Farrell O Mendelsohn, Koen Ameloot, Malcolm Foster, Tim A. Fischell, Helen Parise, Felix Mahfoud
Journal: Circulation (2024)

Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure (BP) among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN have not been formally studied in this indication.
Early Seizure Prophylaxis in Mild and Moderate Traumatic Brain Injury
Authors: Matthew Pease, Adi Mittal, Sara Merkaj, David O. Okonkwo, Jorge A. Gonzalez-Martinez, Jonathan Elmer, Wen-Shyong Liou, Valeria Pingue, Flora M. Hammond, Sergiu Abramovici, James Castellano, Niravkumar Barot
Journal: JAMA Neurology (2024)

Guidelines recommend seizure prophylaxis for early posttraumatic seizures (PTS) after severe traumatic brain injury (TBI). Use of antiseizure medications for early seizure prophylaxis after mild or moderate TBI remains controversial.
Intravesical Interferon Therapy vs Hyaluronic Acid for Pain Among Female Individuals With Interstitial Cystitis
Authors: Si-hong Shen, Liao Peng, Xiao Zeng, Jie Zhang, Hong Shen, De-yi Luo
Journal: JAMA Network Open (2024)

Interstitial cystitis (IC) is a debilitating condition. Although viral infection is a potential etiological cause, few studies have detected the effect of antiviral treatment.
Paid Family Leave Programs—Understanding the Consequences for Infant Health
Authors: Katherine A. Ahrens, Teresa Janevic, Jennifer A. Hutcheon
Journal: JAMA Pediatrics (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Transcatheter or Surgical Treatment of Aortic-Valve Stenosis
Authors: Stefan Blankenberg, Moritz Seiffert, Reinhard Vonthein, Helmut Baumgartner, Sabine Bleiziffer, Michael A. Borger, Yeong-Hoon Choi, Peter Clemmensen, Jochen Cremer, Martin Czerny, Nina Diercks, Ingo Eitel, Stephan Ensminger, Derk Frank, Norbert Frey, Andreas Hagendorff, Christian Hagl, Christian Hamm, Utz Kappert, Matthias Karck, Won-Keun Kim, Inke R. König, Markus Krane, Ulf Landmesser, Axel Linke, Lars S. Maier, Steffen Massberg, Franz-Josef Neumann, Hermann Reichenspurner, Tanja K. Rudolph, Christof Schmid, Holger Thiele, Raphael Twerenbold, Thomas Walther, Dirk Westermann, Erion Xhepa, Andreas Ziegler, Volkmar Falk
Journal: New England Journal of Medicine (2024)

Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcatheter aortic-valve implantation (TAVI) and surgical aortic-valve replacement (SAVR), data are lacking on the appropriate treatment strategy in routine clinical practice.
Systemic Lupus Erythematosus
Authors: Caroline H. Siegel, Lisa R. Sammaritano
Journal: JAMA (2024)

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and immune-mediated injury to multiple organ systems, including the mucocutaneous, musculoskeletal, hematologic, and kidney systems. Approximately 3.4 million people worldwide have received a diagnosis of SLE.
<scp>d</scp>-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women
Authors: Gail Hayward, Sam Mort, Alastair D. Hay, Michael Moore, Nicholas P. B. Thomas, Johanna Cook, Jared Robinson, Nicola Williams, Nicola Maeder, Rebecca Edeson, Marloes Franssen, Jenna Grabey, Margaret Glogowska, Yaling Yang, Julie Allen, Christopher C. Butler
Journal: JAMA Internal Medicine (2024)

Recurrent urinary tract infection (UTI) is a common debilitating condition in women, with limited prophylactic options. d-Mannose has shown promise in trials based in secondary care, but effectiveness in placebo-controlled studies and community settings has not been established.
Naked-Eye 3-Dimensional Vision Training for Myopia Control
Authors: Rui Xie, Feng Zhao, Jianhong Yu, Bin Luo, Zhidong Jiang, Xiaoyun Qiu, Yingpin Cao, Yuxia Yang, Kezhe Chen, Yuan Zhang, Xiaoling Luo, Zhirong Wang, Yingting Zhu, Yehong Zhuo
Journal: JAMA Pediatrics (2024)

Importance Early onset of myopia increases the risk of high myopia, which can lead to irreversible retinal damage and even loss of central vision. Objective To investigate the efficacy and safety of naked-eye 3-dimensional vision training (NVT) in preventing the progression of myopia in children. Design, Setting, and Participants This randomized clinical trial was conducted in 3 hospitals from May 25, 2022, to February 24, 2023. Participants were children (aged 6-18 years) who had a diagnosis of myopia with a spherical equivalent refraction of −0.75 to −6.00 diopters (D). Intervention Children in the intervention group received 20 minutes of NVT treatment every day, whereas children in the control group lived as usual without vision training. Main Outcome and Measure The primary outcome was the change in axial length at 6 months. Spherical equivalent refraction (SER) was included as a secondary outcome. Results Among 263 participants, 125 (47.5%) were male and 138 (52.5%) were female; the mean (SD) age was 10.3 (1.9) years (range, 6.1-15.6 years). A total of 227 patients (86.3%) completed the 6-month follow-up, including 102 in the intervention group and 125 in the control group. In the intervention group, the changes in axial length and SER at 6 months were 0.18 mm (95% CI, 0.16 to 0.20 mm) and −0.25 D (95% CI, −0.31 to −0.19 D), respectively. In the control group, the changes in axial length and SER at 6 months were 0.23 mm (95% CI, 0.21 to 0.25 mm) and −0.35 D (95% CI, −0.41 to −0.30 D), respectively. The differences in AL and SER between the 2 groups were significant (AL difference: −0.06 mm; 95% CI, −0.09 to −0.03; P &amp;amp;lt; .001; SER difference: 0.10 D; 95% CI, 0.02 to 0.19; P = .02). No study-related adverse reactions were reported during follow-up. Conclusions and Relevance NVT is a safe and promising means to control myopia progression in children with good adherence. Trial Registration ClinicalTrials.gov Identifier: NCT05468775
Harnessing artificial intelligence for prostate cancer management
Authors: Lingxuan Zhu, Jiahua Pan, Weiming Mou, Longxin Deng, Yinjie Zhu, Yanqing Wang, Gyan Pareek, Elias Hyams, Benedito A. Carneiro, Matthew J. Hadfield, Wafik S. El-Deiry, Tao Yang, Tao Tan, Tong Tong, Na Ta, Yan Zhu, Yisha Gao, Yancheng Lai, Liang Cheng, Rui Chen, Wei Xue
Journal: Cell Reports Medicine (2024)

Prostate cancer (PCa) is a common malignancy in males. The pathology review of PCa is crucial for clinical decision-making, but traditional pathology review is labor intensive and subjective to some extent. Digital pathology and whole-slide imaging enable the application of artificial intelligence (AI) in pathology. This review highlights the success of AI in detecting and grading PCa, predicting patient outcomes, and identifying molecular subtypes. We propose that AI-based methods could collaborate with pathologists to reduce workload and assist clinicians in formulating treatment recommendations. We also introduce the general process and challenges in developing AI pathology models for PCa. Importantly, we summarize publicly available datasets and open-source codes to facilitate the utilization of existing data and the comparison of the performance of different models to improve future studies.